Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment

Abstract Background Prostate cancer (PCa) is the most prevalent genitourinary malignancy in men, with a significant proportion of patients developing biochemical recurrence (BCR) after treatment. The immune microenvironment and metabolic alterations have crucial implications for the tumorigenesis an...

Full description

Bibliographic Details
Main Authors: Bintao Hu, Xi Zhang, Shiqing Zhu, Chengwei Wang, Zhiyao Deng, Tao Wang, Yue Wu
Format: Article
Language:English
Published: BMC 2024-01-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-024-01672-3
_version_ 1827328124462825472
author Bintao Hu
Xi Zhang
Shiqing Zhu
Chengwei Wang
Zhiyao Deng
Tao Wang
Yue Wu
author_facet Bintao Hu
Xi Zhang
Shiqing Zhu
Chengwei Wang
Zhiyao Deng
Tao Wang
Yue Wu
author_sort Bintao Hu
collection DOAJ
description Abstract Background Prostate cancer (PCa) is the most prevalent genitourinary malignancy in men, with a significant proportion of patients developing biochemical recurrence (BCR) after treatment. The immune microenvironment and metabolic alterations have crucial implications for the tumorigenesis and progression of PCa. Therefore, identifying metabolic genes associated with the immune microenvironment holds promise for predicting BCR and improving PCa prognosis. Methods In this study, ssGSEA and hierarchical clustering analysis were first conducted to evaluate and group PCa samples, followed by the use of the ESTIMATE and CIBERSORT algorithms to characterize the immunophenotypes and tumor microenvironment. The differential metabolic genes (MTGs) between groups were utilized to develop a prognostic-related signature. The predictive performance of the signature was assessed by principal component analysis (PCA), receiver operating characteristic (ROC) curve analysis, survival analysis, and the TIDE algorithm. A miRNA-MTGs regulatory network and predictive nomogram were constructed. Moreover, the expression of prognostic MTGs in PCa was detected by RT‒qPCR. Results PCa samples from the TCGA cohort were separated into two groups: the immune-low group and immune-high group. Forty-eight differentially expressed MTGs between the groups were identified, including 37 up-regulated and 11 down-regulated MTGs. Subsequently, CEL, CYP3A4, and PDE6G were identified as the genes most strongly associated with the BCR of PCa patients and these genes were utilized to establish the MTGs-based prognostic signatures. PCA, ROC curves analysis, Kaplan–Meier survival analysis, and the nomogram all showed the good predictive ability of the signature regardless of clinical variables. Furthermore, the MTGs-based signature was indicated as a potential predictive biomarker for immunotherapy response. Nine miRNAs involved in the regulation of prognostic MTGs were determined. In addition to the CEL gene, the PDE6G and CYP3A4 genes were expressed at higher levels in PCa samples. Conclusions The MTGs-based signature represents a novel approach with promising potential for predicting BCR in PCa patients.
first_indexed 2024-03-07T15:13:23Z
format Article
id doaj.art-c0280c85b9b64707b88b483406a3733e
institution Directory Open Access Journal
issn 2047-783X
language English
last_indexed 2024-03-07T15:13:23Z
publishDate 2024-01-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj.art-c0280c85b9b64707b88b483406a3733e2024-03-05T18:04:05ZengBMCEuropean Journal of Medical Research2047-783X2024-01-0129111910.1186/s40001-024-01672-3Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironmentBintao Hu0Xi Zhang1Shiqing Zhu2Chengwei Wang3Zhiyao Deng4Tao Wang5Yue Wu6Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologySchool of Nursing, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background Prostate cancer (PCa) is the most prevalent genitourinary malignancy in men, with a significant proportion of patients developing biochemical recurrence (BCR) after treatment. The immune microenvironment and metabolic alterations have crucial implications for the tumorigenesis and progression of PCa. Therefore, identifying metabolic genes associated with the immune microenvironment holds promise for predicting BCR and improving PCa prognosis. Methods In this study, ssGSEA and hierarchical clustering analysis were first conducted to evaluate and group PCa samples, followed by the use of the ESTIMATE and CIBERSORT algorithms to characterize the immunophenotypes and tumor microenvironment. The differential metabolic genes (MTGs) between groups were utilized to develop a prognostic-related signature. The predictive performance of the signature was assessed by principal component analysis (PCA), receiver operating characteristic (ROC) curve analysis, survival analysis, and the TIDE algorithm. A miRNA-MTGs regulatory network and predictive nomogram were constructed. Moreover, the expression of prognostic MTGs in PCa was detected by RT‒qPCR. Results PCa samples from the TCGA cohort were separated into two groups: the immune-low group and immune-high group. Forty-eight differentially expressed MTGs between the groups were identified, including 37 up-regulated and 11 down-regulated MTGs. Subsequently, CEL, CYP3A4, and PDE6G were identified as the genes most strongly associated with the BCR of PCa patients and these genes were utilized to establish the MTGs-based prognostic signatures. PCA, ROC curves analysis, Kaplan–Meier survival analysis, and the nomogram all showed the good predictive ability of the signature regardless of clinical variables. Furthermore, the MTGs-based signature was indicated as a potential predictive biomarker for immunotherapy response. Nine miRNAs involved in the regulation of prognostic MTGs were determined. In addition to the CEL gene, the PDE6G and CYP3A4 genes were expressed at higher levels in PCa samples. Conclusions The MTGs-based signature represents a novel approach with promising potential for predicting BCR in PCa patients.https://doi.org/10.1186/s40001-024-01672-3Prostate cancerImmune microenvironmentBiochemical recurrenceImmune geneMetabolic genesPrognostic signature
spellingShingle Bintao Hu
Xi Zhang
Shiqing Zhu
Chengwei Wang
Zhiyao Deng
Tao Wang
Yue Wu
Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
European Journal of Medical Research
Prostate cancer
Immune microenvironment
Biochemical recurrence
Immune gene
Metabolic genes
Prognostic signature
title Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
title_full Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
title_fullStr Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
title_full_unstemmed Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
title_short Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
title_sort identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
topic Prostate cancer
Immune microenvironment
Biochemical recurrence
Immune gene
Metabolic genes
Prognostic signature
url https://doi.org/10.1186/s40001-024-01672-3
work_keys_str_mv AT bintaohu identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT xizhang identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT shiqingzhu identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT chengweiwang identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT zhiyaodeng identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT taowang identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment
AT yuewu identificationandvalidationofanindividualizedmetabolicprognosticsignatureforpredictingthebiochemicalrecurrenceofprostatecancerbasedontheimmunemicroenvironment